Metsera, Inc., the Technology sector company, was revisited by a Wall Street analyst yesterday. Analyst Cerena Chen from Wells Fargo maintained a Buy rating on the stock and has a $65.00 price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Cerena Chen’s rating is based on the anticipation of a catalyst-rich second half of 2025 for Metsera, Inc., particularly with the upcoming MET-097i readouts in September. These readouts are expected to provide insights into the efficacy and tolerability of the treatment, which are crucial for the company’s obesity franchise. The narrowing of the Phase 2b VESPER-1 readout to September and the interim analysis of VESPER-3, facilitated by faster-than-expected enrollment, are seen as positive indicators of Metsera’s clinical trial execution.
Cerena Chen also highlights the potential for significant upside in Metsera’s stock, with a 10% increase expected if the MET-097i high dose achieves a weight loss of 15-20% over 28 weeks. This would align with the GLP-1 class, with further differentiation expected in tolerability. Additionally, there is a 25% upside potential if efficacy exceeds 20% weight loss, although a downside risk exists if weight loss falls below 15%. The upcoming data from Amylin and oral candidates towards the end of 2025 further supports the Buy rating, as improvements in tolerability are anticipated to enhance the competitive positioning of Metsera’s offerings.
In another report released on July 23, Bank of America Securities also maintained a Buy rating on the stock with a $45.00 price target.